Is Bal Pharma a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bal Pharma Ltd is a below average quality company .

Is Bal Pharma undervalued or overvalued?

The key valuation ratios of Bal Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Bal Pharma share price return in the past 10 years?

Bal Pharma Ltd share price has appreciated 11.3% annually (CAGR) over the past ten years.

Is Bal Pharma a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bal Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Bal Pharma Ltd - Stock Valuation and Financial Performance

Name: Bal Pharma
Brand: Bal Pharma

BSE: 524824 | NSE: BALPHARMA | Pharmaceuticals & Drugs | Small Cap

Place order

Bal Pharma Share Price

₹96.30 -3.92 -3.91%
as on 19-Apr'24 15:32

10 Year X-Ray of Bal Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	9.7%	7.9%	5.8%	6.9%	7.6%	9%	-0.3%	10.8%	7.6%	7.7%	-
Value Creation Index ⓘ	-0.3	-0.4	-0.6	-0.5	-0.5	-0.4	-1.0	-0.2	-0.5	-0.5	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	179	187	198	226	208	223	171	249	280	303	326
Sales YoY Gr.	-	4.6%	5.6%	14.3%	-8.1%	7.4%	-23.5%	46.1%	12.5%	8.1%	-
Adj EPS ⓘ	4.3	2.8	1.7	2.3	3.5	4.6	-6.6	7	4.4	4.5	3.9
YoY Gr.	-	-34.3%	-41.1%	41.8%	51.3%	29.7%	-243.6%	NA	-37.1%	1.1%	-
BVPS (₹) ⓘ	43.5	41.6	42.5	47	51	54.2	46.5	52.9	57.7	60.3	62.4
Adj Net Profit ⓘ	4.7	3.6	2.1	3.3	5	6.5	-9.3	10.4	6.5	7	6
Cash Flow from Ops. ⓘ	13.3	14.4	1.3	6.4	12.6	11.6	21.7	10.2	30.6	5.1	-
Debt/CF from Ops. ⓘ	3.9	3.4	54.6	11.7	7.2	9.1	4.6	10.2	3.2	24.7	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	6%	7.9%	21.1%	8.1%
Adj EPS ⓘ	0.5%	4.7%	NA	1.1%
BVPSⓘ	3.7%	3.4%	9%	4.6%
Share Price	11.3%	6.2%	16.8%	34.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	10	6.8	3.8	5.4	7.2	8.7	-13.1	14.3	7.8	7.6	6.4
Op. Profit Mgn % ⓘ	10	9.4	8.7	8.9	11	9.2	4.2	11.4	8.4	9.1	9.3
Net Profit Mgn % ⓘ	2.7	1.9	1.1	1.5	2.4	2.9	-5.5	4.2	2.3	2.3	1.9
Debt to Equity ⓘ	1.1	0.9	1.3	1.1	1.3	1.4	1.5	1.3	1.2	1.3	-
Working Cap Days ⓘ	189	193	211	221	290	303	386	270	273	296	146
Cash Conv. Cycle ⓘ	76	72	71	78	112	129	179	106	96	102	29

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 21.10%

Sales growth is good in last 4 quarters at 10.38%

Return on Equity has declined versus last 3 years average to 6.40%

Net Profit has been subdued in last 3 years 0.00%

Debt to equity has increased versus last 3 years average to 1.32

Latest Financials - Bal Pharma Ltd.

	Standalone	Consolidated
TTM EPS (₹)	3.9	2.2
TTM Sales (₹ Cr.)	326	327
BVPS (₹.) ⓘ	62.4	40.6
Reserves (₹ Cr.) ⓘ	83	48
P/BV ⓘ	1.61	2.47
PE ⓘ	25.66	45.02

From the Market
52 Week Low / High (₹)	70.50 / 132.20
All Time Low / High (₹)	1.60 / 167.90
Market Cap (₹ Cr.)	158
Equity (₹ Cr.)	15.8
Face Value (₹)	10
Industry PE ⓘ	47.6

Management X-Ray of Bal Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Bal Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Bal Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	179	187	198	226	208	223	171	249	280	303
Operating Expenses ⓘ	161	170	181	206	185	203	164	223	257	277
Manufacturing Costs	23	25	24	27	24	27	21	24	32	41
Material Costs	84	87	94	104	88	104	76	140	153	156
Employee Cost	28	32	36	41	50	48	49	40	44	52
Other Costs ⓘ	27	25	27	33	23	24	18	19	28	28
Operating Profit ⓘ	18	18	17	20	23	20	7	27	23	26
Operating Profit Margin (%)	10.0%	9.4%	8.7%	8.9%	11.0%	9.2%	4.1%	10.6%	8.4%	8.6%
Other Income ⓘ	1	1	1	3	2	3	4	3	6	2
Interest ⓘ	7	7	6	8	9	13	13	12	11	12
Depreciation ⓘ	5	7	7	6	7	6	7	7	7	7
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	7	5	5	9	8	4	-9	10	12	9
Tax ⓘ	2	1	2	3	3	-2	0	1	3	2
Profit After Tax	5	4	3	5	6	7	-9	9	9	6
PAT Margin (%)	2.8%	2.1%	1.4%	2.4%	2.9%	3.0%	-5.2%	3.6%	3.1%	2.0%
Adjusted EPS (₹)	4.6	3.1	2.2	3.8	4.2	4.8	-6.3	6.1	5.8	3.9
Dividend Payout Ratio (%)	22%	32%	46%	27%	24%	21%	0%	16%	17%	26%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	48	54	55	67	72	77	66	78	85	95
Share Capital ⓘ	11	13	13	14	14	14	14	15	15	16
Reserves ⓘ	37	41	42	52	58	63	52	64	71	79
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	51	47	66	70	84	97	94	99	92	117
Long Term Debt	8	7	16	18	35	29	23	24	27	31
Short Term Debt	43	40	50	52	49	68	71	75	65	87
Trade Payables	34	38	47	54	50	47	39	49	72	91
Others Liabilities ⓘ	22	25	26	29	45	36	40	36	40	45
Total Liabilities ⓘ	155	164	193	219	251	257	239	262	290	348
Fixed Assets
Gross Block	91	96	106	66	71	76	82	86	92	107
Accumulated Depreciation	36	44	50	6	13	19	26	33	39	44
Net Fixed Assetsⓘ	55	52	56	60	58	57	56	53	53	63
CWIP ⓘ	0	1	4	2	0	0	0	0	1	0
Investmentsⓘ	0	1	1	0	7	7	7	8	8	8
Inventories	32	36	42	54	66	70	68	60	74	98
Trade Receivables	45	45	57	61	64	66	52	69	78	95
Cash Equivalents	3	5	4	5	4	4	3	4	5	7
Others Assetsⓘ	19	25	29	37	51	53	53	67	70	76
Total Assets ⓘ	155	164	193	219	251	257	239	262	290	348

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	13	14	1	6	13	12	22	10	31	5
PBT ⓘ	7	5	5	9	8	4	-9	10	12	9
Adjustment ⓘ	10	12	11	15	15	16	17	17	14	19
Changes in Working Capital ⓘ	-3	-1	-14	-16	-10	-6	14	-17	6	-22
Tax Paid ⓘ	-1	-1	-1	-1	-1	-2	0	0	-1	-1
Cash Flow From Investing Activity ⓘ	-7	-6	-14	-8	-16	-12	-3	-7	-13	-22
Capex	-7	-5	-14	-8	-4	-5	-4	-3	-8	-15
Net Investments	0	0	0	0	0	-2	0	-1	-1	-1
Others ⓘ	0	-1	0	0	-12	-5	0	-3	-5	-7
Cash Flow From Financing Activityⓘ	-8	-7	12	2	4	0	-20	-3	-17	17
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	3	0	4
Net Proceeds from Borrowing ⓘ	1	0	10	0	17	-5	-9	0	3	4
Interest Paid ⓘ	-7	-7	-6	-8	-9	-12	-12	-12	-10	-12
Dividend Paid ⓘ	-1	-2	-2	-2	-2	-1	-1	0	-1	-2
Others ⓘ	0	1	10	12	-3	19	3	5	-8	23
Net Cash Flow ⓘ	-2	2	0	0	1	0	-1	0	0	0

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	11.06	7.9	5.18	8.76	8.56	9.07	-12.47	12.61	10.47	6.8
ROCE (%)	13.77	11.3	10.07	12.77	11.76	9.95	2.09	12.57	12.28	10.25
Asset Turnover Ratio	1.2	1.2	1.13	1.13	0.89	0.88	0.69	1	1.02	0.95
PAT to CFO Conversion(x)	2.6	3.5	0.33	1.2	2.17	1.71	N/A	1.11	3.44	0.83
Working Capital Days
Receivable Days	89	87	92	93	109	106	125	89	96	104
Inventory Days	66	65	70	76	105	111	147	93	87	103
Payable Days	143	150	166	176	215	171	209	114	144	191

Bal Pharma Ltd Stock News

Bal Pharma Ltd FAQs

What is the share price of Bal Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Bal Pharma on 19-Apr-2024 15:32 is ₹96.30.

What is the market cap of Bal Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 19-Apr-2024 15:32 the market cap of Bal Pharma stood at ₹158.4.

What is the P/E ratio of Bal Pharma?

The latest P/E ratio of Bal Pharma as of 19-Apr-2024 15:32 is 25.66.

What is the P/B ratio of Bal Pharma?

The latest P/B ratio of Bal Pharma as of 19-Apr-2024 15:32 is 1.61.

What is the 52-week high and low of Bal Pharma?

The 52-week high of Bal Pharma is ₹132.2 and the 52-week low is ₹70.50.

What is the TTM revenue of Bal Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bal Pharma is ₹325.9 ( Cr.) .

About Bal Pharma Ltd

Bal Pharma Limited is a leading Indian Pharmaceutical Company with 25+ years of experience, specialized in Prescription Drugs, Generic & OTC Products, Intravenous Infusion and Bulk Actives.

The company strives hard to improve the quality of life for patients by providing them products that are Safe, Effective, High Quality and Affordable.

The company’s API and FDF are produced at world class manufacturing facilities. APIs are largely exported to Europe, Far East, Latin America, Africa, Middle East and other World markets. The FDF are exported to Semi-Regulated, Non-Regulated market and are now foraying to regulated market. The company is also one of the strong contenders for World Tender Business.

Business area of the company

The company is engaged in the manufacturing and selling of pharmaceutical products. The company caters to both domestic and international markets.

Business segments

API Intermediate: The company’s API (Active Pharmaceutical Ingredients) business began in 1996 with a simple objective of facilitating the manufacture of niche molecules that have been able to take the benefits of vertical integration to international and domestic markets. Bal Pharma’s API business has the competence and knowledge to undertake more than 30 different types of complex chemical reactions.

Finished formulations: Bal Pharma has a winning formula of cutting edge technology, handled by a highly qualified professional with a passion to deliver beyond excellence. The company is successfully exporting Finished Formulation to many countries. The company offers extensive range of products covering dosage forms - tablets, capsules, syrups, suspensions, IV infusions, Ophthalmic, creams and ointments to various Semi-Regulated markets.

Ayurveda/Herbal: Ayurveda is India’s traditional, natural system of medicine that has been practiced for more than 5,000 years. Ayurveda is a Sanskrit word that, when literally translated, means 'science of life' or 'practices of longevity.' Ayurveda provides an integrated approach to preventing and treating illness through lifestyle interventions and natural therapies. The company’s objective of providing “Good life to All” launched its Ayurvedic Division - Bal Vedics in 2003. Bal Vedics is dedicated to bringing out ‘nature’s best’ through International Quality Natural Formulations that combine traditional Indian Wisdom of medicine with Scientific Manufacturing.